SHR-1501, Adebrelimab
Phase 2Monoclonal antibody
Shanghai Hengrui Pharmaceutical Co., Ltd.SHR-1501, Adebrelimab is one of 13 small molecule programs targeting Malignant Tumors. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Malignant Tumors
#DrugCompanyPhaseTrials
1Beyfortus
BeiGenePhase 2
Stivarga
BayerPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Taxotere
AAvyxa
Phase 2
LBL-007
BeiGenePhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 1
Abraxane
Bristol-Myers SquibbPhase 1
Al18f-NOTA-FAPI
CCancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
Anti-PD-1 Antibody
Boehringer IngelheimPhase 1
SHR-1501, Adebrelimab
Shanghai Hengrui Pharmaceutical Co., Ltd.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR-1501, Adebrelimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details